Image Place holder

Julio Pow-Sang, MD

Chair, Department of Genitourinary Oncology

Specialty: Urology
Program: Genitourinary Oncology


Cancer Focus: Bladder Cancer, Prostate Cancer, Testicular Cancer

A native of Peru, Dr. Pow-Sang received his medical degree from the Universidad Autonoma de Guadalajara in Mexico.  He completed residencies in surgery and urology at the University of Miami School of Medicine and a fellowship in urological oncology at the University of Florida in Gainesville. Dr. Pow-Sang is a principal investigator for numerous clinical trials in genitourinary cancer and is a member of the prostate cancer guidelines panel for the National Comprehensive Cancer Network and member of the Florida Prostate Cancer Advisory Council.  In addition, he is on the editorial board and a reviewer for many professional journals, as well as a member of professional medical societies in the U.S., Europe and South America. In addition to his medical studies, Dr. Pow-Sang has a master’s in business administration from the University of South Florida. Dr. Pow-Sang is fluent in English, Spanish and French, and speaks conversational German and Italian.   He has been named one of the Best Doctors in America since 1998.  

Education & Training


  • University of Florida College of Medicine - Urologic Oncology


  • University of Miami School of Medicine - General Surgery
  • University of Miami School of Medicine - Urology

Medical School:

  • University Autonoma De Guadalajara, Mexico - MD
Start Year: 1994 End Year: H. Lee Moffitt Award of Excellence, Sponsor: Moffitt Cancer Center
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Moreira SG J, Pow-Sang J. Evaluation and management of adrenal masses. Cancer Control. Jul 2002.9(4):326-334. Pubmedid: 12228758.
  • Fink AKC, DeRenzis AC, Awasthi S, Jahan N, Johnstone PAS, Pow-Sang J, Torres-Roca J, Grass D, Fernandez D, Naghavi A, Tan S, Manley B, Li R, Poch M, Yu A, Little N, Bass E, Ercole CE, Katsoulakis E, Burri R, Smith R, Stanley NB, Vadaparampil ST, Yamoah K. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study. Cancer Med. 2023 Jan.12(2):1869-1877. Pubmedid: 35796421.
  • Awasthi S, Mahal BA, Park JY, Creed JH, Williams VL, Elkenawi A, Meadows SO, Pow-Sang JM, Lu-Yao G, Kelly WK, Lang DY, Zgibor J, Rebbeck TR, Yamoah K. Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysis. Prostate Cancer P D. 2022 Sep.25(3):547-552. Pubmedid: 35194179.
  • Youssef I, Poch M, Raghunand N, Pow-Sang J, Johnstone PAS. Analysis of MRI radiomic pelvimetry and correlation with margin status after robotic prostatectomy. Can J Urol. 2022 Feb.29(1):10976-10978. Pubmedid: 35150217.
  • Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, Li R, Manley B, Fernandez D, Naghavi A, Gage K, Lu-Yao G, Katsoulakis E, Burri RJ, Leone A, Ercole CE, Palmer JD, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, Yamoah K. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease. J Natl Cancer Inst. 2022 Dec.114(12):1656-1664. Pubmedid: 36053178. Pmcid: PMC9745424.
  • Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Ne. 2022 Dec.20(12):1288-1298. Pubmedid: 36509074.
  • Kumar NB, Hogue S, Pow-Sang J, Poch M, Manley BJ, Li R, Dhillon J, Yu A, Byrd DA. Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome. Cancers (Basel). 2022 Aug.14(16). Pubmedid: 36010981. Pmcid: PMC9406482.
  • Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr.81(4):325-330. Pubmedid: 33303244.
  • Lin HY, Tseng TS, Wang X, Fang Z, Zea AH, Wang L, Pow-Sang J, Tangen CM, Goodman PJ, Wolk A, Håkansson N, Kogevinas M, Llorca J, Brenner H, Schöttker B, Castelao JE, Gago-Dominguez M, Gamulin M, Lessel D, Claessens F, Joniau S, The Practical Consortium, Park JY. Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status. Cancers (Basel). 2022 Apr.14(8). Pubmedid: 35454886. Pmcid: PMC9024489.
  • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
  • Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert S, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 May.113(5):532-542. Pubmedid: 33146385. Pmcid: PMC8096374.
  • Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
  • Mason NT, Burkett JM, Nelson RS, Pow-Sang JM, Gatenby RA, Kubal T, Peabody JW, Letson GD, McLeod HL, Zhang J. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. Am Health Drug Benefits. 2021 Mar.14(1):15-20. Pubmedid: 33841621. Pmcid: PMC8025923.
  • Parikh N, Keshishian E, Manley B, Grass GD, Torres-Roca J, Boulware D, Feuerlein S, Pow-Sang JM, Bagla S, Yamoah K, Bhatia S. Effectiveness and Safety of Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms from Benign Prostatic Hyperplasia in Men with Concurrent Localized Prostate Cancer. J Vasc Interv Radiol. 2021 Jul.32(7):1053-1061. Pubmedid: 33794373.
  • Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 Jan.39(1):72.e1-72.e5. Pubmedid: 33036902.
  • Yamoah K, Lal P, Awasthi S, Naghavi AO, Rounbehler RJ, Gerke T, Berglund AE, Pow-Sang JM, Schaeffer EM, Dhillon J, Park JY, Rebbeck TR. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. Prostate. 2021 Feb.81(2):109-117. Pubmedid: 33141952. Pmcid: PMC7810127.
  • Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Spratt DE, Teply BA, Tward J, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Ne. 2021 Feb.19(2):134-143. Pubmedid: 33545689.
  • Araujo A, Cook LM, Frieling JS, Tan W, Copland JA, Kohli M, Gupta S, Dhillon J, Pow-Sang J, Lynch CC, Basanta D. Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33567529. Pmcid: PMC7915310.
  • Lin HY, Huang PY, Cheng CH, Tung HY, Fang Z, Berglund AE, Chen A, French-Kwawu J, Harris D, Pow-Sang J, Yamoah K, Cleveland JL, Awasthi S, Rounbehler RJ, Gerke T, Dhillon J, Eeles R, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Neal DE, Nielsen SF, Nordestgaard BG, Gronberg H, Wiklund F, Giles GG, Haiman CA, Travis RC, Stanford JL, Kibel AS, Cybulski C, Khaw KT, Maier C, Thibodeau SN, Teixeira MR, Cannon-Albright L, Brenner H, Kaneva R, Pandha H, Srinivasan S, Clements J, Batra J, Park JY. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 Apr.11(1):9264. Pubmedid: 33927218. Pmcid: PMC8084951.
  • Liveringhouse C, Sim A, Yamoah K, Poch M, Wilder RB, Pow-Sang J, Johnstone PAS. Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer. Rep Pract Oncol Radiother. 2021 Apr.26(2):188-195. Pubmedid: 34211768. Pmcid: PMC8241300.
  • Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
  • Lu H, Parra NA, Qi J, Gage K, Li Q, Fan S, Feuerlein S, Pow-Sang J, Gillies R, Choi JW, Balagurunathan Y. Repeatability of Quantitative Imaging Features in Prostate Magnetic Resonance Imaging. Front Oncol. 2020 May.10:551. Pubmedid: 32457827. Pmcid: PMC7221156.
  • Hajiran A, Pow-Sang J. Re: Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. J Urol. 2020 Jul.204(1):159. Pubmedid: 32191584.
  • Hajiran A, Pow-Sang J. Editorial Comment. J Urol. 2020 Aug.204(2):266. Pubmedid: 32437261.
  • Kumar NB, Pow-Sang J, Spiess P, Dickinson S, Schell MJ. A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy. Oncotarget. 2020 Apr.11(14):1218-1234. Pubmedid: 32292572. Pmcid: PMC7147089.
  • Parikh N, Keshishian E, Sharma A, Roca M, Manley B, Poch M, Grass GD, Torres-Roca J, Boulware D, Johnstone P, Montejo M, Smith J, Pow-Sang J, Yamoah K. Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis. Adv Radiat Oncol. 2020 Apr.5(5):905-909. Pubmedid: 33083652. Pmcid: PMC7557125.
  • Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2019 May.17(5):479-505. Pubmedid: 31085757.
  • Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K. Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study. Cancer Epidemiol Biomarkers Prev. 2019 Mar.28(3):570-577. Pubmedid: 30413401. Pmcid: PMC8100999.
  • Parra NA, Lu H, Choi J, Gage K, Pow-Sang J, Gillies RJ, Balagurunathan Y. Habitats in DCE-MRI to Predict Clinically Significant Prostate Cancers. Tomography. 2019 Mar.5(1):68-76. Pubmedid: 30854444. Pmcid: PMC6403034.
  • Parra NA, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y. Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors. Oncotarget. 2019 Mar.10(21):2113. Pubmedid: 31007853. Pmcid: PMC6459347.
  • Aydin AM, Pow-Sang JM. Editorial Comment. J Urol. 2019 Jun.201(6):1125-1126. Pubmedid: 30864907.
  • Li Q, Lu H, Choi J, Gage K, Feuerlein S, Pow-Sang JM, Gillies R, Balagurunathan Y. Radiological semantics discriminate clinically significant grade prostate cancer. Cancer Imaging. 2019 Dec.19(1):81. Pubmedid: 31796094. Pmcid: PMC6889697.
  • Torres-Roman JS, Ruiz EF, Martinez-Herrera JF, Mendes Braga SF, Taxa L, Saldaña-Gallo J, Pow-Sang MR, Pow-Sang JM, La Vecchia C. Prostate cancer mortality rates in Peru and its geographical regions. BJU Int. 2019 Apr.123(4):595-601. Pubmedid: 30281883.
  • Patel SY, Garcia Getting RE, Alford B, Hussein K, Schaible BJ, Boulware D, Lee JK, Gilbert SM, Powsang JM, Sexton WJ, Spiess PE, Poch MA. Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center. World J Surg. 2018 Sep.42(9):2701-2707. Pubmedid: 29750321. Pmcid: PMC7771278.
  • Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ. Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clin Genitourin Cancer. 2018 Oct.16(5):e1003-e1013. Pubmedid: 29859736.
  • Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov.4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
  • Chipollini J, Alford B, Boulware DC, Forget P, Gilbert SM, Lockhart JL, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA, Patel SY. Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center. BMC Anesthesiol. 2018 Nov.18(1):157. Pubmedid: 30390636. Pmcid: PMC6215353.
  • Williams VL, Awasthi S, Fink AK, Pow-Sang JM, Park JY, Gerke T, Yamoah K. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015. Cancer Med. 2018 May.7(5):2160-2171. Pubmedid: 29601662. Pmcid: PMC5943433.
  • Azizi M, Peyton CC, Boulware DC, Chipollini J, Juwono T, Pow-Sang JM, Spiess PE. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection. Eur Urol Focus. 2018 Jun.5(6):1085-1090. Pubmedid: 29937330. Pmcid: PMC7771277.
  • Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul.7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
  • Chipollini J, Tang DH, Manimala N, Gilbert SM, Pow-Sang JM, Sexton WJ, Poch MA, Spiess PE. Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer. Urol Oncol. 2018 Jan.36(1):14.e1-14.e5. Pubmedid: 29032883.
  • Lin HY, Huang PY, Chen DT, Tung HY, Sellers TA, Pow-Sang J, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Hamdy F, Neal DE, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Batra J, Teixeira MR, Pandha H, Lu YJ, Park JY. AA9int: SNP interaction pattern search using non-hierarchical additive model set. Bioinformatics. 2018 Dec.34(24):4141-4150. Pubmedid: 29878078. Pmcid: PMC6289141.
  • Parra AN, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y. Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors. Oncotarget. 2018 Dec.9(98):37125-37136. Pubmedid: 30647849. Pmcid: PMC6324677.
  • Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J. Green tea extract for prevention of prostate cancer progression in patients on active surveillance. Oncotarget. 2018 Dec.9(102):37798-37806. Pubmedid: 30701033. Pmcid: PMC6340872.
  • Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget. 2017 Nov.8(58):99093-99103. Pubmedid: 29228755. Pmcid: PMC5716795.
  • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. Urology. 2017 May.103:142-148. Pubmedid: 28011275.
  • Lin HY, Chen DT, Huang PY, Liu YH, Ochoa A, Zabaleta J, Mercante DE, Fang Z, Sellers TA, Pow-Sang JM, Cheng CH, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Hamdy F, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Batra J, Teixeira MR, Pandha H, Lu YJ, Park JY. SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. Bioinformatics. 2017 Mar.33(6):822-833. Pubmedid: 28039167. Pmcid: PMC5860469.
  • Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. Urology. 2017 Jul.105:108-112. Pubmedid: 28342928.
  • Zargar H, Lamb AD, Rocco B, Porpiglia F, Liatsikos E, Davis J, Coelho RF, Pow-Sang JM, Patel VR, Murphy DG. Salvage robotic prostatectomy for radio recurrent prostate cancer: technical challenges and outcome analysis. Minerva Urol Nefrol. 2017 Feb.69(1):26-37. Pubmedid: 27579821.
  • Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?. Clin Genitourin Cancer. 2017 Dec.15(6):696-703. Pubmedid: 28566202.
  • Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. J Urol. 2017 Dec.198(6):1346-1352. Pubmedid: 28652123.
  • Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug.15(4):e583-e589. Pubmedid: 28410909. Pmcid: PMC7771283.
  • Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. World J Urol. 2017 Apr.35(4):657-663. Pubmedid: 27495912.
  • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Author Reply. Urology. 2017 05.103:148. Pubmedid: 28108090.
  • Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ, Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH, Lindblom A, Swerdlow A, Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Flesch-Janys D, Edwards DR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton-Culver H, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang-Claude J, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa J, Clements JA, Knight JA, Peto J, Cunningham JM, Pow-Sang J, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeney LA, Massuger LF, Fitzgerald LM, Cook LS, Cannon-Albright L, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, ...
  • Kumar NB, Pow-Sang JM, Spiess PE, Park JY, Chornokur G, Leone AR, Phelan CM. Chemoprevention in African American Men With Prostate Cancer. Cancer Control. 2016 Oct.23(4):415-423. Pubmedid: 27842331.
  • Gilbert SM, Pow-Sang JM, Xiao H. Geographical Factors Associated With Health Disparities in Prostate Cancer. Cancer Control. 2016 Oct.23(4):401-408. Pubmedid: 27842329.
  • Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct.7(43):70794-70802. Pubmedid: 28053292. Pmcid: PMC5340117.
  • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov.34(11):1567-1573. Pubmedid: 27072536.
  • Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res. 2016 Nov.22(22):5605-5616. Pubmedid: 27220961. Pmcid: PMC5122466.
  • Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol Oncol. 2016 Mar.34(3):122.e1-122.e7. Pubmedid: 26546482. Pmcid: PMC4761468.
  • Mouraviev V, Klein M, Schommer E, Thiel DD, Samavedi S, Kumar A, Leveillee RJ, Thomas R, Pow-Sang JM, Su LM, Mui E, Smith R, Patel V. Urology residents experience comparable workload profiles when performing live porcine nephrectomies and robotic surgery virtual reality training modules. J Robot Surg. 2016 Mar.10(1):49-56. Pubmedid: 26753619.
  • Sharma P, Zargar-Shoshtari K, Pow-Sang JM. Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA. 2016 Mar.2(1):FSO72. Pubmedid: 28031932. Pmcid: PMC5137959.
  • Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology. 2016 Jul.93:130-134. Pubmedid: 27041469.
  • Cook LM, Araujo A, Pow-Sang JM, Budzevich MM, Basanta D, Lynch CC. Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer. Sci Rep. 2016 Jul.6:29384. Pubmedid: 27411810. Pmcid: PMC4944130.
  • Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. J Urol. 2016 Jan.195(1):47-52. Pubmedid: 26235376. Pmcid: PMC4924593.
  • Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 1.2016. J Natl Compr Canc Ne. 2016 Jan.14(1):19-30. Pubmedid: 26733552.
  • Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Clin Genitourin Cancer. 2016 Feb.14(1):82-88. Pubmedid: 26411593.
  • Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis. Clin Genitourin Cancer. 2016 Feb.14(1):89-95. Pubmedid: 26453395.
  • Russell CM, Sharma P, Agarwal G, Fisher JS, Richard GJ, Spiess PE, Pow-Sang JM, Poch MA, Sexton WJ. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?. Can J Urol. 2016 Feb.23(1):8127-8134. Pubmedid: 26892052.
  • Gwede CK, Davis SN, Wilson S, Patel M, Vadaparampil ST, Meade CD, Rivers BM, Yu D, Torres-Roca J, Heysek R, Spiess PE, Pow-Sang J, Jacobsen P. Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. Am J Health Promot. 2016 Dec.29(6):393-401. Pubmedid: 24968183. Pmcid: PMC4277494.
  • Zargar-Shoshtari K, Ashouri K, Sharma P, Baumgarten A, Sexton WJ, Pow-Sang J, Spiess PE. Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes. ANZ J Surg. 2016 Dec.86(1-2):44-48. Pubmedid: 26370725.
  • Zargar-Shoshtari K, Spiess PE, Berglund AE, Sharma P, Powsang JM, Giuliano A, Magliocco AM, Dhillon J. Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort. Clin Genitourin Cancer. 2016 Aug.14(4):346-351. Pubmedid: 26794389. Pmcid: PMC7771549.
  • Dossett LA, Castner NB, Pow-Sang JM, Abbott AM, Sondak VK, Sarnaik AA, Zager JS. Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. J Am Coll Surg. 2016 Apr.222(4):702-709. Pubmedid: 26875071. Pmcid: PMC4871144.
  • Agarwal G, Buethe D, Russell C, Luchey A, Pow-Sang JM. Long term survival and predictors of disease reclassification in patients on an active surveillance protocol for prostate cancer. Can J Urol. 2016 Apr.23(2):8215-8219. Pubmedid: 27085826.
  • Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE. Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy. Int Braz J Urol. 2015 Sep.41(5):911-919. Pubmedid: 26689516. Pmcid: PMC4756967.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015 Oct.33(10):1585-1592. Pubmedid: 25552207.
  • Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct.8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
  • Mendez MH, Passoni NM, Pow-Sang J, Jones JS, Polascik TJ. Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population. J Endourol. 2015 Oct.29(10):1193-1198. Pubmedid: 26058496.
  • Balducci L, Pow-Sang JM. Letter From the Editors: A New Step Rather Than a New Era. Cancer Control. 2015 Oct.22(4):381. Pubmedid: 27062729.
  • Luchey AM, Agarwal G, Espiritu PN, Lockhart JL, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center. World J Urol. 2015 Nov.33(11):1763-1768. Pubmedid: 25774005.
  • Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. J Urol. 2015 Nov.194(5):1220-1225. Pubmedid: 26055823.
  • Quinn GP, Block RG, Clayman ML, Kelvin J, Arvey SR, Lee JH, Reinecke J, Sehovic I, Jacobsen PB, Reed D, Gonzalez L, Vadaparampil ST, Laronga C, Lee MC, Pow-Sang J, Eggly S, Franklin A, Shah B, Fulp WJ, Hayes-Lattin B. If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients' medical records. J Oncol Pract. 2015 Mar.11(2):137-144. Pubmedid: 25549654. Pmcid: PMC4799849.
  • Zargar-Shoshtari K, Sharma P, Espiritu P, Kurian T, Pow-Sang JM, Mangar D, Sexton WJ, Spiess PE. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol. 2015 Mar.33(3):112.e23-112.e29. Pubmedid: 25555854.
  • Agarwal G, Valderrama O, Luchey AM, Pow-Sang JM. Robotic-Assisted Laparoscopic Radical Prostatectomy. Cancer Control. 2015 Jul.22(3):283-290. Pubmedid: 26351883.
  • Toloza EM, Pow-Sang JM. Applications and Advances in Robotic-Assisted Oncological Surgery: Ready to Dock the 'Bot. Cancer Control. 2015 Jul.22(3):278-279. Pubmedid: 26351882.
  • Gopman JM, Djajadiningrat RS, Baumgarten AS, Espiritu PN, Horenblas S, Zhu Y, Protzel C, Pow-Sang JM, Kim T, Sexton WJ, Poch MA, Spiess PE. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int. 2015 Aug.116(2):196-201. Pubmedid: 25777366.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug.33(8):339.e17-339.e23. Pubmedid: 26094169.
  • Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug.22(4):7882-7889. Pubmedid: 26267026.
  • Balducci L, Pow-Sang JM. Colorectal Cancer: The Last Nail in the Coffin for Androgen Deprivation Therapy for Prostate Cancer?. Cancer Control. 2015 Apr.22(2):259-260. Pubmedid: 26068774.
  • Baumgarten AS, Alhammali E, Hakky TS, Espiritu PN, Pow-Sang JM, Sexton WJ, Lockhart JL, Protzel C, Hakenberg O, Muneer A, Spiess PE. Salvage surgical resection for isolated locally recurrent inguinal lymph node metastasis of penile cancer: international study collaboration. J Urol. 2014 Sep.192(3):760-764. Pubmedid: 24603104.
  • Davis SN, Sutton SK, Vadaparampil ST, Meade CD, Rivers BM, Patel MV, Torres-Roca JF, Heysek RV, Spiess P, Pow-Sang J, Jacobsen PB, Gwede CK. Informed decision making among first-degree relatives of prostate cancer survivors: a pilot randomized trial. Contemp Clin Trials. 2014 Nov.39(2):327-334. Pubmedid: 25465497. Pmcid: PMC4274628.
  • Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Ne. 2014 May.12(5):686-718. Pubmedid: 24812137.
  • Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Jul.32(5):619-624. Pubmedid: 24495448.
  • Chornokur G, Amankwah EK, Davis SN, Phelan CM, Park JY, Pow-Sang J, Kumar NB. Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. Prostate Cancer. 2014 Jan.2013:384594. Pubmedid: 24386569. Pmcid: PMC3872424.
  • Sverrisson EF, Nguyen H, Kim T, Pow-Sang JM. Primary cryosurgery for clinically localized prostate cancer--do perioperative tumor characteristics correlate with post-treatment biopsy results?. Urology. 2014 Feb.83(2):376-378. Pubmedid: 24315311.
  • Gallaher J, Cook LM, Gupta S, Araujo A, Dhillon J, Park JY, Scott JG, Pow-Sang J, Basanta D, Lynch CC. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastas. 2014 Dec.31(8):991-999. Pubmedid: 25173680. Pmcid: PMC5399888.
  • Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. J Urol. 2014 Aug.192(2):350-356. Pubmedid: 24530987.
  • Carastro LM, Lin HY, Park HY, Kim D, Radlein S, Hampton KK, Hakam A, Zachariah B, Pow-Sang J, Park JY. Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance. Prostate Cancer. 2014 Aug.2014:129582. Pubmedid: 25097786. Pmcid: PMC4109114.
  • Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiother Oncol. 2014 Apr.111(1):126-131. Pubmedid: 24746567.
  • Chornokur G, Han G, Tanner R, Lin HY, Green BL, Pow-Sang J, Phelan CM. High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: results from a pilot study. Cancer Lett. 2013 May.331(2):154-157. Pubmedid: 23268329. Pmcid: PMC3603576.
  • Amankwah EK, Anegbe E, Park H, Pow-Sang J, Hakam A, Park JY. miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian J Androl. 2013 Mar.15(2):226-230. Pubmedid: 23353719. Pmcid: PMC3705740.
  • Ercole CE, Pow-Sang JM, Spiess PE. Update in the surgical principles and therapeutic outcomes of inguinal lymph node dissection for penile cancer. Urol Oncol. 2013 Jul.31(5):505-516. Pubmedid: 21481617.
  • Pow-Sang JM. The improving landscape of urologic oncology. Cancer Control. 2013 Jul.20(3):158-159. Pubmedid: 23811699.
  • Nguyen HD, Allen BJ, Pow-Sang JM. Focal cryotherapy in the treatment of localized prostate cancer. Cancer Control. 2013 Jul.20(3):177-180. Pubmedid: 23811701.
  • Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate cancer, version 1.2014. J Natl Compr Canc Ne. 2013 Dec.11(12):1471-1479. Pubmedid: 24335682.
  • Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2012 Sep.10(9):1081-1087. Pubmedid: 22956807.
  • Buethe DD, Pow-Sang J. Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer. J Natl Compr Canc Ne. 2012 Sep.10(9):1101-1110. Pubmedid: 22956809.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar.33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Mar.2011(S3). Pubmedid: 22422102. Pmcid: PMC3300067.
  • Rivers BM, August EM, Quinn GP, Gwede CK, Pow-Sang JM, Green BL, Jacobsen PB. Understanding the psychosocial issues of African American couples surviving prostate cancer. J Cancer Educ. 2012 Jun.27(3):546-558. Pubmedid: 22544536. Pmcid: PMC4497555.
  • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan.2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
  • Spiess PE, Kurian T, Lin HY, Rawal B, Kim T, Sexton WJ, Pow-Sang JM. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012 Dec.110(11 Pt B):E470-E474. Pubmedid: 22519938.
  • Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012 Dec.110(11 Pt B):E475-E480. Pubmedid: 22564727.
  • Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy. 2012 Apr.4(4):373-382. Pubmedid: 22512631. Pmcid: PMC4241355.
  • Lin HY, Park HY, Radlein S, Mahajan NP, Sellers TA, Zachariah B, Pow-Sang J, Coppola D, Ganapathy V, Park JY. Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness. Urology. 2011 Oct.78(4):971.e1-971.e9. Pubmedid: 21802122. Pmcid: PMC3190039.
  • Rivers BM, August EM, Gwede CK, Hart A, Donovan KA, Pow-Sang JM, Quinn GP. Psychosocial issues related to sexual functioning among African-American prostate cancer survivors and their spouses. Psychooncology. 2011 Jan.20(1):106-110. Pubmedid: 20187071. Pmcid: PMC4509592.
  • Pow-Sang JM. Editorial comment. Urology. 2011 Feb.77(2):367. Pubmedid: 21295251.
  • Correa JJ, Pow-Sang JM. Optimizing cancer control and functional outcomes following robotic prostatectomy. Cancer Control. 2010 Oct.17(4):233-244. Pubmedid: 20861811.
  • Pow-Sang JM. Progress in treatment of genitourinary malignancies. Cancer Control. 2010 Oct.17(4):212. Pubmedid: 20861808.
  • Kolla SB, Ercole C, Spiess PE, Pow-Sang JM, Sexton WJ. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int. 2010 Nov.106(10):1494-1498. Pubmedid: 20230378.
  • Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Ne. 2010 Feb.8(2):162-200. Pubmedid: 20141676.
  • Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol. 2010.8(1):3-13. Pubmedid: 20205984. Pmcid: PMC3277948.
  • Caso J, Seigne J, Back M, Spiess PE, Pow-Sang J, Sexton WJ. Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urology. 2009 Sep.182(3):887-893. Pubmedid: 19616230.
  • Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genetics. 2009 Oct.41(10):1116-1121. Pubmedid: 19767753. Pmcid: PMC2846760.
  • Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009 Nov.27(5):496-501. Pubmedid: 18639470. Pmcid: PMC2743955.
  • Coppola D, Oliveri C, Sayegh Z, Boulware D, Takahashi Y, Pow-Sang J, Djeu JY, Wang HG. Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer. 2008 Sep.6(2):117-121. Pubmedid: 18824435. Pmcid: PMC2626142.
  • Park J, Zheng W, Kim D, Cheng J, Kumar N, Ahmad N, Pow-Sang J. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2008 Jan.31(5):359-365. Pubmedid: 18037591.
  • Pow-Sang J. Pure and robotic-assisted laparoscopic radical prostatectomy: technology and techniques merge to improve outcomes. Expert Rev Anticancer Ther. 2008 Jan.8(1):15-19. Pubmedid: 18095879.
  • Fishman M, Hunter T, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo M, Noyes D, Mahany J, Lee J, Cantor A, Messina J, Seigne J, Pow-Sang J, JanssenW, Antonia S. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother. 2008 Jan.31(1):72-80. Pubmedid: 18157014.
  • Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Krischer JP. Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clin Med Urol. 2008 Apr.1:1-14. Pubmedid: 20354574. Pmcid: PMC2846655.
  • Rodriguez A, Kapoor R, Pow-Sang J. Laparoscopic extraperitoneal radical prostatectomy in complex surgical cases. J Urol. 2007 May.177(5):1765-1770. Pubmedid: 17437812.
  • Pow-Sang J, Velasquez J, Myers M, Rodriguez A, Kang L. Pure laparoscopic and robotic-assisted laparoscopic radical prostatectomy in the management of prostate cancer. Cancer Control. 2007 Jul.14(3):250-257. Pubmedid: 17615531.
  • Correa J, Politis C, Rodriguez A, Pow-Sang J. Laparoscopic retroperitoneal lymph node dissection in the management of testis cancer. Cancer Control. 2007 Jul.14(3):258-264. Pubmedid: 17615532.
  • Mohler J, Babaian R, Bahnson R, Boston B, D'Amico A, Eastham J, Hauke R, Huben R, Kantoff P, Kawachi M, Kuettel M, Lange P, Logothetis C, MacVicar G, Pollack A, Pow-Sang J, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, TwardowskiP, Urban D, Walsh P. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2007 Aug.5(7):650-683. Pubmedid: 17692170.
  • Park J, Tanner J, Sellers T, Huang Y, Stevens C, Dossett N, Shankar R, Zachariah B, Heysek R, Pow-Sang J. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology. 2007 Aug.70(2):374-379. Pubmedid: 17826523.
  • Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007.59(2):163-168. Pubmedid: 18001210. Pmcid: PMC2435485.
  • Kumar NBB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer. 2007.59(2):169-175. Pubmedid: 18001211. Pmcid: PMC2442460.
  • Torres-Roca JF, Cantor AB, Shukla S, Montejo ME, Friedland J, Seigne JD, Heysek R, Heysek, Randy, Pow-Sang J. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol. 2006 Sep.24(5):384-390. Pubmedid: 16962486.
  • Torres-Roca J, Cantor A, Shukla S, Montejo M, Friedland J, Seigne J, Heysek R, Pow-Sang J. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol. 2006 Oct.24(5):384-390. Pubmedid: 16962486.
  • Patterson S, Wei S, Chen X, Sallman D, Gilvary D, Zhong B, Pow-Sang J, Yeatman T, Djeu J. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene. 2006 Oct.25(45):6113-6122. Pubmedid: 16652143.
  • Rodriguez A, Kang L, Politis C, Wade M, Sexton W, Miranda-Sousa A, Pow-Sang JM. Delayed metastatic renal carcinoma to prostate. Urology. 2006 Mar.67(3):623.e7-623.10. Pubmedid: 16527593.
  • Rodriguez A, Pow-Sang J. Laparoscopic surgery in urologic oncology. Cancer Control. 2006 Jul.13(3):169-178. Pubmedid: 16885912.
  • Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY. Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol. 2006 Jan.175(1):108-112. Pubmedid: 16406883.
  • Pow-Sang J. Uro-oncology: improved techniques produce better outcomes. Cancer Control. 2006.13(3):156-156. Pubmedid: 16885910.
  • Gwede C, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen P. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer. 2005 Oct.104(7):1381-1390. Pubmedid: 16080181.
  • Rodriguez A, Burday D, Sexton W, Ahmad N, Pow-Sang J. Urothelial carcinoma in a child. Arch Esp Urol. 2005 Jun.58(5):473-475. Pubmedid: 16078794.
  • Kumar N, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May.59(2):141-147. Pubmedid: 15042614.
  • Vadaparampil S, Jacobsen P, Kash K, Watson I, Saloup R, Pow-Sang J. Factors predicting prostate specific antigen testing among first-degree relatives of prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 2004 May.13(5):753-758. Pubmedid: 15159306.
  • Park J, Chen L, Shade K, Lazarus P, Seigne J, Patterson S, Helal M, Pow-Sang J. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol. 2004 Jun.171(6 Pt 1):2484-2488. Pubmedid: 15126881.
  • Moreira S, Seigne J, Ordorica R, Marcet J, Pow-Sang J, Lockhart J. Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma. BJU Int. 2004 Jan.93(1):31-35. Pubmedid: 14678363.
  • Jacobsen P, Lamonde L, Honour M, Kash K, Hudson P, Pow-Sang J. Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology. 2004 Feb.13(2):80-85. Pubmedid: 14872526.
  • Pow-Sang J. Genitourinary oncology: the continuous evolution of multimodality treatments. Cancer Control. 2004.11(6):351-351. Pubmedid: 15625521.
  • Webster C, Bukkapatnam R, Seigne J, Pow-Sang J, Hoffman M, Helal M, Ordorica R, Lockhart J. Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years). J Urol. 2003 Jan.169(1):174-176. Pubmedid: 12478129.
  • Shukla A, Pow-Sang J, Helal M, Seigne J, Ordorica R, Lockhart J. Urinary incontinence after continent urinary diversion using cecal wrap or plicated ileum: a patient questionnaire review. Urology. 2003 Feb.61(2):328-331. Pubmedid: 12597940.
  • Chen L, Elahi A, Pow-Sang J, Lazarus P, Park J. Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol. 2003 Dec.170(6 Pt 1):2471-2474. Pubmedid: 14634453.
  • Thurman S, Robinson L, Ahmad N, Pow-Sang J, Lockhart J, Seigne J. Investigation of the safety and accuracy of intraoperative gamma probe directed biopsy of bone scan detected rib abnormalities in prostatic adenocarcinoma. J Urol. 2003 Apr.169(4):1341-1344. Pubmedid: 12629356.
  • Keehn C, Pow-Sang J, Ahmad N. Pathologic quiz case: a 57-year-old man with hypertension and hypokalemia. Arch Pathol Lab Med. 2003 Apr.127(4):495-496. Pubmedid: 12683884.
  • Mora L, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, FalconeR, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002 Nov.62(22):6659-6666. Pubmedid: 12438264.
  • Antonia S, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo M, Friberg M, Alsarraj M, Mahany J, Pow-Sang J, Cantor A, Janssen W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002 May.167(5):1995-2000. Pubmedid: 11956426.
  • Patterson S, Balducci L, Pow-Sang J. Controversies surrounding androgen deprivation for prostate cancer. Cancer Control. 2002 Jul.9(4):315-325. Pubmedid: 12228757.
  • Pow-Sang J. The spectrum of genitourinary malignancies. Cancer Control. 2002 Jul.9(4):275-276. Pubmedid: 12228752.
  • Pow-Sang M, Benavente V, Pow-Sang J, Morante C, Meza L, Baker M, Pow-Sang JM. Cancer of the penis. Cancer Control. 2002 Jul.9(4):305-314. Pubmedid: 12228756.
  • Bukkapatnam R, Pow-Sang J. Radical prostatectomy in the management of clinically localized prostate cancer. Cancer Control. 2001 Nov.8(6):496-502. Pubmedid: 11807419.
  • Pow-Sang J. Prostate cancer at the beginning of the 21st century: more options and better outcomes. Cancer Control. 2001 Nov.8(6):480-481. Pubmedid: 11807417.
  • Hoff B, Pow-Sang J. Observation in the management of localized prostate cancer. Cancer Control. 2001 Mar.8(2):151-154. Pubmedid: 11326169.
  • Pow-Sang J. Clinically localized prostate cancer: the paradox of paradoxes. Cancer Control. 2001 Mar.8(2):126. Pubmedid: 11326166.
  • Diaz J, Pow-Sang J, Mora L, Seigne J, Cantor A, Dalton W. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol. 2000 Jul.5(4):149-154. Pubmedid: 10869956.
  • Pow-Sang J, Seigne J. Contemporary management of superficial bladder cancer. Cancer Control. 2000 Jul.7(4):335-339. Pubmedid: 10895127.
  • Pow-Sang J. Bladder cancer: one enemy, many fronts. Cancer Control. 2000 Jul.7(4):307. Pubmedid: 10895125.
  • Feygelman V, Pow-Sang JM, Friedland JL, Sanders RM. Needle imaging during ultrasound-guided permanent prostate implants. Tech Urol. 1999 Sep.5(3):143-145. Pubmedid: 10527257.
  • Seigne J, Turner J, Diaz J, Hackney J, Pow-Sang J, Helal M, Lockhart J, Yu H. A feasibility study of gene gun mediated immunotherapy for renal cell carcinoma. J Urol. 1999 Oct.162(4):1259-1263. Pubmedid: 10492175.
  • Mora L, Moscinski L, Diaz J, Blair P, Cantor A, Pow-Sang J. Stage B Prostate Cancer: Correlation of DNA Ploidy Analysis With Histological and Clinical Parameters. Cancer Control. 1999 Nov.6(6):587-591. Pubmedid: 10756390.
  • Pow-Sang J. Just the Facts, Ma'am. Cancer Control. 1999 Nov.6(6):545-546. Pubmedid: 10756385.
  • Pow-Sang J. Ten best readings on genitourinary tumors. Cancer Control. 1999 Nov.6(6):594-595.
  • Diaz J, Mora L, Austin P, Muro-Cacho C, Cantor A, Nicosia S, Pow-Sang J. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology. 1999 May.53(5):931-938. Pubmedid: 10223486.
  • Masel J, Austin P, Spyropoulos E, Seigne J, Pow-Sang J, Odorica R, Lockhart J. Evaluation of flap valve as an alternative continence mechanism in the Florida pouch. Urology. 1999 Mar.53(3):506-509. Pubmedid: 10096375.
  • Lynch C, Towsley G, Pow-Sang J, Lockhart J, Seigne J. Long-term urodynamic changes of a continent colonic urinary reservoir. J Pelvic Surgeons. 1999.5(1):13-16.
  • Chabarek N, Mora L, Diaz J, Pow-Sang J. La edad como factor de riesgo de complicaciones post-operatorias en prostatectomia radical retropubica. Urologia Panamericana. 1999.11(3):17-19.
  • Pow-Sang J, Friedland J, Seigne J, Feygelman V. Brachytherapy for prostate cancer. Urologia Panamericana. 1999.11(4):24-26.
  • Feygelman V, Pow-Sang J, Friedland J, Sanders R. Needle imaging during ultrasound-guided permanent prostate implants. Tech Urol. 1999.3:143-145.
  • Pow-Sang J. Prostate Cancer: Of Turtles, Birds, and Rabbits. Cancer Control. 1998 Nov.5(6):483-484. Pubmedid: 10761096.
  • Lynch C, Towsley G, Pow-Sang J, Lockhart J. Long-term urodynamic evaluation of a continent urinary reservoir. Prim Care Update Ob Gyns. 1998 Jul.5(4):200. Pubmedid: 10838382.
  • Benson K, Agosti S, Lyman G, Pow-Sang J, Saba H, Balducci L. Estimated blood loss in group O as compared to non-group O radical prostatectomy. Hematology. 1998.3:257-261. Pubmedid: noPMID.
  • Pow-Sang J. Ten best readings on prostate cancer. Cancer Control. 1998.5(6):559-560. Pubmedid: noPMID.
  • Helal M, Austin P, Spyropoulos E, Pow-Sang J, Persky L, Lockhart J. Evaluation and management of parastomal hernia in association with continent urinary diversion. J Urol. 1997 May.157(5):1630-1632. Pubmedid: 9112492.
  • Pow-Sang J, Spyropoulos E, Helal M, Lockhart J. Bladder Replacement and Urinary Diversion After Radical Cystectomy. Cancer Control. 1996 Nov.3(6):512-518. Pubmedid: 10764510.
  • Pow-Sang J, Marshburn J. Clinical Practice Guidelines for Prostate Cancer. Cancer Control. 1996 Nov.3(6):526-530. Pubmedid: 10764513.
  • Mora L, Nicosia S, Pow-Sang J, Ku N, Diaz J, Lockhart J, Einstein, Jr. A. Ancillary techniques in the followup of transitional cell carcinoma: a comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients. J Urol. 1996 Jul.156(1):49-54. Pubmedid: 8648836.
  • Feygelman V, Friedland J, Sanders R, Noriega B, Pow-Sang J. Improvement in dosimetry of ultrasound-guided prostate implants with the use of multiple stabilization needles. Med Dosim. 1996 Dec.21(2):109-112. Pubmedid: 8807612 .
  • Diaz J, Nicosia S, Szakacs J, Pow-Sang J, Saba H. Metastatic Seminoma Simulating Malignant lymphoma in an HIV infected hemophiliac. Leuk Lymphoma. 1996.23:165-171. Pubmedid: 9021701.
  • Rabb H, Borrasa E, Adams R, Pow-Sang J, Ramirez G. Alpha-v/beta-3 and alpha-5/beta-3 integrin expression in cancerous kidney. Am J Nephrol. 1996.16:402-402. Pubmedid: 8886177.
  • Pow-Sang J. Genitourinary cancers:update on detection, treatment, and research. Cancer Control. 1996.6(3):486-487.
  • Pow-Sang J. Ten best readings. Cancer Control. 1996.3(3):542-543.
  • Feygelman V, Friedland JL, Sanders RM, Noriega BK, Pow-Sang JM. Improvement in dosimetry of ultrasound-guided prostate implants with the use of multiple stabilization needles. Med Dosim. 1996.21(2):109-112. Pubmedid: 8807612.
  • Friedland J, Pow-Sang J, Johnson D, Byrnes J. Quality-of-Life Issues Associated With the Treatment of Prostate Cancer. Cancer Control. 1995 Jan.2(1):42-46. Pubmedid: 10887396.
  • Pow-Sang J. Prostate Cancer: Detection and Management. Cancer Control. 1995 Jan.2(1):9. Pubmedid: 10887390.
  • Helal M, Figueroa T, Pow-Sang J, Sanford E, Lockhart J. A trans-reservoir technique for correction of ureterointestinal obstruction in continent urinary diversion. J Urol. 1995 Apr.153(4):1108-1109. Pubmedid: 7869474.
  • Pow-Sang J. Ten best readings in prostate cancer. Cancer Control. 1995.1(2):62-63. Pubmedid: noPMID.
  • Horton J, Pow-Sang J. Continuing medical education. Cancer Control. 1995.2(1):77-81. Pubmedid: noPMID.
  • Pow-Sang J. Contoversias en el manejo de cancer de rinon. Urologia Panamericana. 1995.7:41-46. Pubmedid: noPMID.
  • Pow-Sang J. Carta del editor invitado. Urologia Panamericana. 1995.7:1-2. Pubmedid: noPMID.
  • Diaz J, Nicosia S, Szakacs J, Pow-Sang J, Saba H. Metastatic seminoma simulating malignant lymphoma in an HIV infected hemophiliac. Leuk Lymphoma. 1995.18:179-184. Pubmedid: noPMID.
  • Greene JN, Sandin RL, Fields KK, Moscinski LC, Beatty A, Pow-Sang J, Elfenbein GJ. Hemorrhagic Cystitis in Bone Marrow Transplant Patients: Is It an Infection or Chemotherapy Toxicity?. Cancer Control. 1994 Jul.1(4):411-415. Pubmedid: 10886995.
  • Greene J, Sandin R, Fields K, Moscinski L, Beatty A, Pow-Sang J, Elfenbein G. Hemorrhagic cystitis in bone marrow transplant patients: is it an infection or chemotherapy toxicity?. Cancer Control. 1994.1(4):411-415.
  • Szakacs J, Pow-Sang J. The pathologist's role in multidisciplinary management of bladder cancer. Ann Clin Lab Sc. 1994.24(6):481-488.
  • Helal M, Pow-Sang J, Sanford E, Figueroa E, Lockhart J. Direct (nontunneled) ureterocolonic reimplantation in association with continent reservoirs. J Urol. 1993 Sep.150(3):835-837. Pubmedid: 8345595.
  • Shabaik A, Pow-Sang J, Lockhart J, Nicosia S. Role of DNA image cytometry in the follow-up of patients with urinary tract transitional cell carcinoma. Anal Quant Cytol Histol. 1993 Apr.15(2):115-123. Pubmedid: 8318126.
  • Gray G, Hernandez O, Hebel D, Root M, Pow-Sang J. Antisense DNA inhibition of HA-RAS induced tumor growth in nude mice. Cancer Res. 1993.53:577-580.
  • Helal M, Pow-Sang J, Sanford E, Figueroa T, Lockhart J. Direct (non-tunnelled) uretero-colonic reimplantation in association with continent reservoirs. J Urology. 1993.150:835-837.
  • Pow-Sang JM, Helal M, Figueroa E, Sanford E, Persky L, Lockhart J. Conversion from external appliance wearing or internal urinary diversion to a continent urinary reservoir (Florida pouch I and II): surgical technique, indications and complications. J Urol. 1992 Feb.147(2):356-360. Pubmedid: 1732593.
  • Pow-Sang J, Lockhart J, Helal M, Persky L, Sanford E. The Florida pouch: diversion to minimize obstruction. Contemp Urol. 1992.4(2):20-29.
  • Pow-Sang J, Helal M, Figueroa E, Sanford E, Persky L, Lockhart J. Conversion from external appliance wearing or internal urinary diversion to a continent urinary reservoir (Florida pouch I and II): surgical technique, indications and complications. J Urology. 1992.147:356-360.
  • Pow-Sang J, Lockhart J. Continent urinary diversion: the Florida pouch. Problems In Urology. 1992.6(3):581-586.
  • Klimberg IW, Pow-Sang JM, Cartwright CK, Wajsman Z. Intravesical bacillus Calmette-Guerin for patients with high-risk superficial bladder cancer. Urology. 1991 Feb.37(2):180-184. Pubmedid: 1992591.
  • Lockhart JL, Pow-Sang JM, Persky L, Kahn P, Helal M, Sanford E. A continent colonic urinary reservoir: the Florida pouch. J Urol. 1990 Oct.144(4):864-867. Pubmedid: 2398560.
  • Lockhart JL, Ellis GF, Helal M, Pow-Sang JM. Combined cystourethropexy for the treatment of type 3 and complicated female urinary incontinence. J Urol. 1990 Apr.143(4):722-725. Pubmedid: 2107335.
  • Lockhart J, Pow-Sang J, Persky L, Sanford E. The Florida pouch: a simplified technique for continent urinary diversion. Urologia Panamericana. 1990.2(1):33-39.
  • Lockhart J, Pow-Sang J, Persky L, Kahn P, Vorstman B, Ellis G, Helal M. Detivacao urinaria continente desenvolvida na Florida: uma te cnica para a America Latina. J Bras Urol. 1989.15:115-115.
  • Pow-Sang JM, Klimberg IW, Hackett RL, Wajsman Z. Primary malignant melanoma of the male urethra. J Urol. 1988 Jun.139(6):1304-1306. Pubmedid: 3286893.
  • Pow-Sang JM, Lockhart JL, Suarez A, Lansman H, Politano VA. Female urinary incontinence: preoperative selection, surgical complications and results. J Urol. 1986 Oct.136(4):831-833. Pubmedid: 3761441.
  • Heysek R, Gwede C, Torres-Roca J, Cantor A, Kelley S, Saini A, Pow-Sang J. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy. 5(4):244-250. Pubmedid: 17118318.
  • Barnholtz-Sloan J, Maldonado J, Pow-Sang J, Giuliano A. Incidence trends in primary malignant penile cancer. Urol Oncol. 25(5):361-367. Pubmedid: 17826651.
  • Rodriguez AR, Rachna K, Pow-Sang JM. Laparoscopic extraperitoneal radical prostatectomy: impact of the learning curve on perioperative outcomes and margin status. JSLS. 14(1):6-13. Pubmedid: 20529523. Pmcid: PMC3021300.
  • Sverrisson E, Jones JS, Pow-Sang JM. [Cryosurgery for prostate cancer: a comprehensive review]. Arch Esp Urol. 66(6):546-556. Pubmedid: 23985454.
  • Sverrisson EF, Kim T, Espiritu PN, Sexton WJ, Pow-Sang JM, Dhillon J, Spiess PE. The merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a perplexing issue. Int Braz J Urol. 40(4):493-498. Pubmedid: 25251966.
  • Lue K, Emtage JB, Pariñas MA, Dhillon J, Pow-Sang J. An extramedullary plasmacytoma in the testicle: A case report and review of the literature. Can Urol Assoc J. 9(3-4):E240-E242. Pubmedid: 26085896. Pmcid: PMC4455656.
  • Pow-Sang J, Friedland J, Einstein, Jr. A. Transitional carcinoma of the bladder in the elderly. In: Comprehensive Geriatric Oncology. London. Harwood Academic Publishers; 1998;697-702.
  • Pow-Sang J, Pow-Sang J. Tratado De Urologia Oncologica. 1997.
  • Balducci L, Pow-Sang J, Friedland J, Diaz J. Cancer in the elderly part II: prostate cancer. In: Balducci L, ed. Clinics in geriatric medicine. Philadelphia, PA: Saunders; 1997;283-306.
  • Pow-Sang J, Pow-Sang J. Manual De Urologia, Primera Edicion. Lima, Peru. Editorial Piramide; 1996.
  • Katz M, Sanford E, Valle J, Lowe D, Pow-Sang J, Braman R. 1993;240A.

Patient Comments
Overall Satisfaction

255 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments